Univariate and multivariate analyses in one study identified PR status (P = 0.028), HER2 status (P = 0.044), and clinical T stage (P = 0.016) as independent clinicopathological predictors of pCR in BC patients following NAT. The gene discussed is ERBB2; the disease is breast cancer.